Integrin Beta 4/ITGB4/CD104 Drug Discovery Landscape & Assay Solutions
- By admin
- 04 Sep 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Epithelial Biology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGB4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGB4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ITGB4 Products |
| Gene Delivery | ITGB4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ITGB4 Products |
| Benchmark Ab | Anti-ITGB4 (Sequence of Clinical Candidates) Recombinant positive control. |
View ITGB4 Products |
| Validator | ITGB4 siRNA Set For knockdown verification. |
View ITGB4 Products |
| Related Target A | ITGA6 (Integrin Alpha 6) Obligate heterodimerization partner forming the alpha-6/beta-4 complex. |
View ITGA6 Products |
| Related Target B | LAMA3 (Laminin Subunit Alpha 3) Major component of Laminin-332, the primary ligand for ITGB4. |
View LAMA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Conformation Validation | Co-expressed ITGA6/ITGB4 recombinant proteins with native glycosylation (HEK293). |
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ITGB4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGB4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and conditionally active biologics (CABs). As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-selective activation to avoid on-target, off-tumor toxicities in healthy epithelial tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Biopharma Innovators, Academic Spin-offs | Triple-Negative Breast Cancer, Lung Squamous Cell Carcinoma | Internalization Assay (Need high-purity ECD-Fc) |
| Bispecific / CAR-T | Immunotherapy Biotechs | Solid Tumors, Pancreatic Cancer | Heterodimer Validation (Need Cross-reactive Abs) |
| Small Molecule / Peptide blockers | Oncology Therapeutics Companies | Metastatic Cancers, EMT-driven Resistance | Selectivity Assay (Need Mutant vs WT Proteins) |